Rheumatoid Arthritis 
The MD Magazine Rheumatoid Arthritis condition center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

Latest Headlines

GSK Submits License Application for RA Medication Sirukumab
Sirukumab, a rheumatoid arthritis treatment that has performed well in recent studies, is now awaiting approval in both the United States and Europe.
The FDA today approved its fourth biosimilar, a tumor necrosis factor inhibitor similar to adalimumab.
A group of researchers from Pfizer found that its biosimilar version of rituximab yielded similar clinical responses in patients with rheumatoid arthritis compared with the innovator product Rituxan.
Erelzi, a biosimilar of Enbrel (etanercept), has received FDA approval. Biosimilars are defined by the organization as being “highly similar to an FDA-approved biological product” while demonstrating “clinically meaningful differences in terms of safety and effectiveness.”
Roughly 20% of people with rheumatoid arthritis (RA) also suffer from chronic kidney disease (CKD), though no clear explanation exists as to whether or not that is coincidental.
Enthesitis refers to the instance of inflammation at the point where a tendon joins to a bone. Looking for further insight into the mechanisms behind inflammatory rheumatism, researchers from delved into the roots of Achilles enthesitis and may have emerged with a new approach to treating many rheumatic conditions.
Atop a growing body of research that examines how rheumatoid arthritis (RA) symptoms are dictated by the body’s circadian rhythms, a recent study seems to explain why so many people-RA sufferers included-wake up each day with stiff joints.
Interleukin-1β (IL-1beta), a cytokine that plays in important role in the body’s immune response, turns out to be part of the body’s early defense system for bacterial infections. Anti-inflammation treatments for autoimmune conditions like rheumatoid arthritis (RA) often times inhibit IL-1beta to mitigate the inflammation that it initiates when infection is detected.
The blistering pace of mobile innovation has opened countless doors for clinical application. Built on Apple's ResearchKit platform, GSK's PARADE app seeks to study rheumatoid arthritis patients in their daily lives.

Most Popular


$vacMongoViewPlus$ $vAR$